Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Reports Increase in Q3 Revenues

NEW YORK, Oct. 29 (GenomeWeb News) - Amersham PLC, which General Electric is slated to acquire pending regulatory approval, today reported increased third quarter sales.

 

The London-based company's sales for the quarter came to £393 million ($668.3 million) up from £378 million for the same period last year.

 

Broken down by business, sales in Amersham Health came to £235 million, compared to £222 million in the second quarter of last year, and sales in Amersham Biosciences were nearly flat at £158 million, compared to £156 million for the same period in 2002. 

 

Amersham said the increase in Biosciences revenue came from growth in the protein separations business, for which it said revenues were £67 million this quarter, while sales in discovery systems were £91 million.   The company said that proteomics and bioassay area grew, while it experienced "continued weakness in the sequencing market," and that CodeLink sales steadily increased.

 

Furthermore, the company said that the restructuring program that it announced in February was proceeding ahead of schedule, "and is on track to deliver profitability as planned during 2004."

 

Amersham did not report income, expenses, or assets for the quarter.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more